Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Atyr Pharma Inc (ATYR)

Atyr Pharma Inc (ATYR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 79,912
  • Shares Outstanding, K 98,051
  • Annual Sales, $ 190 K
  • Annual Income, $ -74,120 K
  • EBIT $ -79 M
  • EBITDA $ -79 M
  • 60-Month Beta 0.55
  • Price/Sales 454.91
  • Price/Cash Flow N/A
  • Price/Book 1.28
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.83
  • Most Recent Earnings $-0.14 on 03/05/26
  • Next Earnings Date 05/06/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 224.68% (-269.06%)
  • Historical Volatility 79.84%
  • IV Percentile 55%
  • IV Rank 13.66%
  • IV High 1,155.84% on 10/08/25
  • IV Low 77.30% on 06/16/25
  • Expected Move (DTE 1) 0.2295 (27.73%)
  • Put/Call Vol Ratio 0.03
  • Today's Volume 139
  • Volume Avg (30-Day) 844
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 43,599
  • Open Int (30-Day) 41,989
  • Expected Range 0.5981 to 1.0571

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.16
  • Number of Estimates 2
  • High Estimate -0.15
  • Low Estimate -0.17
  • Prior Year -0.17
  • Growth Rate Est. (year over year) +5.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7900 +4.76%
on 03/19/26
1.1000 -24.76%
on 02/23/26
-0.2224 (-21.18%)
since 02/19/26
3-Month
0.6562 +26.12%
on 01/12/26
1.1100 -25.44%
on 02/19/26
+0.0776 (+10.35%)
since 12/19/25
52-Week
0.6400 +29.31%
on 11/21/25
7.2904 -88.65%
on 07/28/25
-3.0124 (-78.45%)
since 03/19/25

Most Recent Stories

More News
Atyr Pharma: Q4 Earnings Snapshot

Atyr Pharma: Q4 Earnings Snapshot

ATYR : 0.8276 (+1.55%)
aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update

Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis.  Phase 2 EFZO-CONNECT™...

ATYR : 0.8276 (+1.55%)
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class...

ATYR : 0.8276 (+1.55%)
aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference

SAN DIEGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary...

ATYR : 0.8276 (+1.55%)
aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis

Meeting with the FDA to review the results from the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis is scheduled for mid-April 2026. SAN DIEGO, Feb....

ATYR : 0.8276 (+1.55%)
Johnson Fistel Investigates Claims on Behalf of aTyr Pharma, Inc. (ATYR) Shareholders

SAN DIEGO , Dec. 15, 2025 /PRNewswire/ -- Johnson Fistel, PLLP is investigating potential derivative claims on behalf of aTyr Pharma, Inc. (NASDAQ: ATYR) concerning alleged fiduciary breaches...

ATYR : 0.8276 (+1.55%)
ATYR Deadline: ATYR Investors with Losses Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit

NEW YORK , Dec. 8, 2025 /PRNewswire/ --

ATYR : 0.8276 (+1.55%)
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In aTyr To Contact Him Directly To Discuss Their Options...

ATYR : 0.8276 (+1.55%)
ATYR LAWSUIT ALERT: The Gross Law Firm Notifies aTyr Pharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK , Dec. 8, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of  aTyr Pharma, Inc. (NASDAQ: ATYR).

ATYR : 0.8276 (+1.55%)
aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - ATYR

LOS ANGELES , Dec. 8, 2025 /PRNewswire/ -- The DJS Law Group  announces that it is investigating claims on behalf of investors of aTyr Pharma, Inc. ("aTyr" or "the Company") (NASDAQ: ATYR...

ATYR : 0.8276 (+1.55%)

Business Summary

aTyr Pharma, Inc. is a bio-therapeutics company. The Company is involved in the discovery and development of medicines for severe, rare diseases of physiological modulators. aTyr Pharma, Inc. is a based in SAN DIEGO, United States.

See More

Key Turning Points

3rd Resistance Point 0.9066
2nd Resistance Point 0.8757
1st Resistance Point 0.8517
Last Price 0.8276
1st Support Level 0.7968
2nd Support Level 0.7659
3rd Support Level 0.7419

See More

52-Week High 7.2904
Fibonacci 61.8% 4.7499
Fibonacci 50% 3.9652
Fibonacci 38.2% 3.1805
Last Price 0.8276
52-Week Low 0.6400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar